Home » Stocks » CNCE

Concert Pharmaceuticals, Inc. (CNCE)

Stock Price: $3.33 USD -0.09 (-2.63%)
Updated Aug 3, 2021 2:14 PM EDT - Market open
Market Cap 107.14M
Revenue (ttm) 7.90M
Net Income (ttm) -76.96M
Shares Out 33.89M
EPS (ttm) -2.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day August 3
Last Price $3.33
Previous Close $3.42
Change ($) -0.09
Change (%) -2.63%
Day's Open 3.42
Day's Range 3.27 - 3.42
Day's Volume 36,167
52-Week Range 3.23 - 13.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 days ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--The Company will host a conference call and webcast on August 5, 2021 to discuss its second quarter financial results and provide a business ...

5 days ago - Business Wire

Concert Pharmaceuticals Inc (NASDAQ: CNCE) has announced updated data from its ongoing open-label, long-term extension study of CTP-543 in patients with moderate to severe alopecia areata. Alopecia area...

1 month ago - Benzinga

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert will provide an update on the CTP-543 open label, long-term extension study at the 2nd JAK Inhibitors Drug Development Summit.

1 month ago - Business Wire

Concert Pharmaceuticals (CNCE) is developing its lead pipeline candidate, CTP-543, for treating alopecia areata. Two late-stage studies are evaluating the candidate in AA patients to support a potential...

2 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced it has initiated THRIVE-AA2, the second planned Phase 3 clinical trial to evalua...

2 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--In June, Concert will participate virtually in fireside chats at both the Jefferies and JMP Securities healthcare conferences.

2 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #Concert--Concert announced that Vertex purchased the potential future milestones under their 2017 asset purchase agreement relating to VX-561 for $32 million.

2 months ago - Business Wire

Concert (CNCE) delivered earnings and revenue surprises of -1.52% and -99.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert reports financial results for the first quarter of 2021.

2 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #AlopeciaAreata--The Company will host a conference call and webcast on May 4, 2021, to discuss its first quarter 2021 financial results and provide a busines...

3 months ago - Business Wire

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert reports financial results for the year ended December 31, 2020.

5 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--The Company will host a conference call and webcast on February 25, 2021, to discuss 2020 financial results and provide a business update.

5 months ago - Business Wire

The company's experimental schizophrenia drug flopped in a phase 2 study.

6 months ago - The Motley Fool

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert announced its Phase 2 trial to evaluate CTP-692 as an adjunctive treatment in patients with schizophrenia did not meet the primary endpoint.

6 months ago - Business Wire

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today at 8:30 a.m. ET to provide an update on the Company and discuss third quarter 2020 results.

8 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert initiated THRIVE-AA1, a Phase 3 study to evaluate the efficacy and safety of CTP-543 in adults with moderate to severe alopecia areata.

9 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert presented initial data from an ongoing long-term, open-label extension study of CTP-543 in patients with alopecia areata at EADV.

9 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast on November 5, at 8:30 AM to discuss third quarter financial results and provide a business update.

9 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Key findings of the survey show that patients with alopecia areata suffer significantly increased burden of illness.

9 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--The EADV presentation will highlight new CTP-543 data from an ongoing open label extension study in patients with moderate to severe alopecia areata.

9 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert completed enrollment in its Phase 2 trial evaluating CTP-692 as an adjunctive treatment in patients with schizophrenia.

10 months ago - Business Wire

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert to participate in a fireside chat with Jason Butler at The JMP Securities CNS Forum.

11 months ago - Business Wire

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Concert (CNCE) delivered earnings and revenue surprises of 39.71% and 63770.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert will host a conference call and webcast today at 8:30 a.m.

11 months ago - Business Wire

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

LEXINGTON, Mass.--(BUSINESS WIRE)---- $CNCE #CNCE--Concert Pharmaceuticals, Inc.

1 year ago - Business Wire

Today also marked the beginning of bank earnings season, with JPMorgan beating expectations on both earnings and revenues driven by a surge in trading revenue amid the market’s volatile second quarter. ...

Other stocks mentioned: CRDF, IDN, REPH, VRTV
1 year ago - Forbes

Shortly after markets jumped in response to June's jobs report, gains were erased as a surge in coronavirus cases was reported across the country. This puts a damper on the economy's recovery.

Other stocks mentioned: ALPN, MRAM, PIXY, SGBX
1 year ago - Forbes

Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Is (CNCE) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) fell by 1.8% from the previous closing price.

1 year ago - Benzinga

Small Drug Industry Prospects Bright Amid Coronavirus Gloom

Other stocks mentioned: ATXI, MEIP, NERV, OCUL
1 year ago - Zacks Investment Research

Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Concert (CNCE) delivered earnings and revenue surprises of 5.41% and -65.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 year ago - Zacks Investment Research

Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Concert Pharmaceuticals, Inc (CNCE) CEO Roger Tung on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Concert (CNCE) delivered earnings and revenue surprises of 15.29% and -97.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Shares fall hard after a late-stage trial comes up short.

1 year ago - The Motley Fool

Concert announced that it had achieved the primary endpoint in the phase 2 study using CTP-543 to treat patients with alopecia areata.

1 year ago - Seeking Alpha

Concert Pharmaceuticals, Inc. (CNCE) CEO Roger Tung on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Concert (CNCE) delivered earnings and revenue surprises of 15.22% and -83.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

2 years ago - Zacks Investment Research

Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.

2 years ago - Zacks Investment Research

About CNCE

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. Its lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert Pharmaceuticals has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquarter... [Read more...]

Industry
Biotechnology
IPO Date
Feb 13, 2014
CEO
Roger Tung
Employees
71
Stock Exchange
NASDAQ
Ticker Symbol
CNCE
Full Company Profile

Financial Performance

In 2020, CNCE's revenue was $7.90 million, an increase of 633.70% compared to the previous year's $1.08 million. Losses were -$74.77 million, -4.35% less than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for CNCE stock is "Strong Buy." The 12-month stock price forecast is 15.33, which is an increase of 360.36% from the latest price.

Price Target
$15.33
(360.36% upside)
Analyst Consensus: Strong Buy